Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE versus GVS.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of mRNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
GVS is not a recognized drug. No mechanism of action available.
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic